From the Journals
Systematic genetic testing for DDX41 mutations may aid in clinical decision making for adults with MDS or AML.
AMSTERDAM – The telomerase inhibitor may also have disease-modifying properties, investigators suspect.
CHICAGO – 5F9 plus azacitidine eradicated leukemia stem cells in responding patients, providing a mechanism for potential long-term durability.
NEWPORT BEACH, CALIF. – Oral rigosertib plus azacitidine produced a 90% response rate in higher-risk patients with myelodysplastic syndromes who...
NEWPORT BEACH, CALIF. – Patients with more than 60% cytogenetically abnormal cells at transplant had inferior overall survival and relapse-free...
NEWPORT BEACH, CALIF. – The researchers used an algorithm to help predict response or resistance to lenalidomide with a high degree of accuracy....
NEWPORT BEACH, CALIF. – Sorafenib plus GCLAM has shown promise in a phase 1 trial of patients with AML and MDS.
Chemotherapy for solid tumors is associated with an increased risk of therapy-related myelodysplastic syndromes or acute myeloid leukemia (tMDS/...